Axonics reports Q4 EPS 1c, consensus (24c)

Reports Q4 revenue $85.9M, consensus $83.2M. "This quarter’s record results reflect the growing demand for our best-in-class incontinence products," said Raymond W. Cohen, CEO. "Our U.S. commercial team is continuing to take advantage of increased patient awareness and the overwhelmingly positive physician response to the Axonics F15(TM) recharge-free sacral neuromodulation system while leveraging cross selling opportunities with Bulkamid(R). Our unique hydrogel generated another record revenue quarter and during 2022, Bulkamid was used to treat over 50,000 women with stress urinary incontinence."